top-home.jpg

Shareholder Update October 2017

Starpharma and Peter Mac Cancer Centre awarded DEP® Grant

AstraZeneca presents first DEP® candidate as Bcl2/xL inhibitor

DEP® docetaxel positive phase 1 results; phase 2 commences

Starpharma annual report and full year financial results

         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products are based on VivaGel ® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties.  VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and has recently completed clinical development for the prevention of recurrent BV.  Starpharma has also signed separate licence agreements with Ansell Limited and Okamoto Industries. Inc., to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect TM  brand.  

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery.

 

A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

 

 
         

© Starpharma Holdings Limited 2017